Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
“All-Japan” System Needed to Contend with Top Global Drug Makers: JPMA R&D Head
Yoshinori Ikeura, chairman of the Japan Pharmaceutical Manufacturers Association’s (JPMA) R&D Committee and site head of Takeda Pharmaceutical’s Shonan Research Center, told Jiho in a recent interview that “No Japanese drug maker, not even Takeda, can rival the top big…
To read the full story
Related Article
- JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
- JPMA to Start Educational Program for Biopharmaceutical Manufacturing Next Spring: Biopharmaceutical Chief
September 4, 2015
- Introduction of GDP Guideline Would Require Investment in Distribution Systems: JPMA Quality Chief
August 19, 2015
- Govt’s Policy Blueprint Will Lead to Soaring R&D Costs, More Early-Stage Projects: JPMA Drug Evaluation Chief
August 14, 2015
- JPMA IP Committee Chair Predicts “Minimum Standard” for Data Protection Period for Drugs
August 5, 2015
- “Humanitarian Trials” Hefty Burden on Drug Makers: JPMA Regulatory Head
July 10, 2015
ORGANIZATION
- Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
June 9, 2026
- Employees of 9 Pharma Firms Team Up for LGBTQ+ Inclusion
June 8, 2026
- Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
- Labor Group Urges MHLW to Support Pharma Talent Development
June 3, 2026
- Labor Group Urges Govt to View Pharma as Investment, Not Cost
June 1, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…